Acute pain in oncology: specific features and treatment options. What is new?
Open Access
- 18 December 2024
- journal article
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 65-78
Abstract
Background: Cancer patients experience acute pain at various the stages of antitumor therapy, which can reduce the patient's commitment to treatment and trust in the doctor, therefore, rapid relief of acute pain is very important. Objective: The aims of the article is to describe the options for acute pain relief in oncology, to characterize the main groups of analgetics, to present data of clinical trials and clinical cases of the use of Tafalgin — the new generation drug from the group of central analgesics.Methods: Analysis of the literature on pain therapy in cancer therapy, and own data within the framework of the multicenter study “Observational program for monitoring the effectiveness and safety of Tafalgin® in real clinical practice — NIKITA”.Results: The classification of acute pain in cancer patients in cancer therapy is proposed, analgesics and the features of their use depending on the intensity of pain are described. The results of Tafalgin use show that in 15 minutes after its subcutaneous administration there was a decrease in the intensity of pain by 59.6 %. The duration of analgesia reached 9.35 ± 6.3 hours. An acceptable level of pain relief was achieved in 84 % of patients. 19 mild and moderate adverse events were detected in 15 patients.Conclusion: Acute pain in cancer patients continues to be a problem, despite the large number of analgesics, so the introduction into clinical practice of a new effective analgesic Tafalgin might ensure pain control.Keywords
This publication has 33 references indexed in Scilit:
- Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspectiveBiochemical Pharmacology, 2020
- Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelinesSupportive Care in Cancer, 2020
- The MASCC/ISOO mucositis guidelines 2019: the second set of articles and future directionsSupportive Care in Cancer, 2020
- Postoperative acute pain challenges in patients with cancerBest Practice & Research Clinical Anaesthesiology, 2019
- Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosisCancer Medicine, 2017
- Tramadol with or without paracetamol (acetaminophen) for cancer pain2017
- Nonsteroidal Anti-inflammatory Drugs and the Risk for Anastomotic FailureJAMA Surgery, 2015
- Multidisciplinary Team Contributions Within a Dedicated Outpatient Palliative Radiotherapy Clinic: A Prospective Descriptive StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Tapentadol hydrochloride: A centrally acting oral analgesicClinical Therapeutics, 2009
- Determining the Incidence of Pain Flare Following Palliative Radiotherapy for Symptomatic Bone Metastases: Results From Three Canadian Cancer CentersInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009